Online Program

Return to main conference page

All Times EDT

Friday, September 24
Fri, Sep 24, 2:15 PM - 3:30 PM
Virtual
Tools to Enable the Use of R by the Biopharmaceutical Industry in a Regulatory Setting

Panel Discussion (303523)

*Keaven M. Anderson, Merck & Co., Inc. 
*Paulo Bargo, Janssen R&D 
*Marly Gotti, Biogen 
*Douglas Kelkhoff, Roche / Genentech 
*Juliane Manitz, EMD Serono, Inc. 
*Andy Nicholls, GSK 
*Joseph Rickert, RStudio 
*Yilong Zhang, Merck & Co., Inc. 

Keywords: software validation, risk assessment, R package

Following the presentations by Paul Schuette and Mark Padgham, we would like to engage in an interactive discussion with the audience. Representatives from the R validation hub executive committee are joining the conversation. We hope to discuss different tools to support R-based submissions in a biopharmaceutical regulatory setting with special attention to the risk-based approach for assessing R package accuracy. We also would like to hear back from the audience about their experiences and questions. Generally, we differentiate two types of R packages: 1) Core and recommended packages that are shipped with the basic installation and a rigorous software development lifecycle assures minimal risk, and 2) Contributed packages that may vary in their accuracy and development rigor, which could be assessed by various metrics. The R validation hub focuses their attention on validating contributed packages. They have developed some of the tools that provide workflow to evaluate the quality of a set of R packages: The R package riskmetric, an associated shiny application to perform risk assessments, and discuss things to consider when testing R packages.